SynthesisFrontiers in endocrinology2025
Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modeling Complex Developmental Disease: The Case of Polycystic Kidney Disease.Journal of developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the clinical features and effects of octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Methods: Databases were searched for randomized controlled trials (RCTs) evaluating octreotide long-acting release (LAR) in ADPKD from inception to December 2024. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. Meta-analysis was performed using Stata 16. Results: A total of six randomized controlled trials were included. Meta-analysis using a fixed-effects model showed no statistically significant difference in glomerular filtration rate (GFR) between the two groups [SMD = -0.020 (-0.250, 0.210), P = 0.864]. Meta-analysis using a random-effects model showed no statistically significant difference in total kidney volume (TKV) between the two groups [SMD= -0.001(-0.376,0.374), P = 0.996]. A fixed-effects model meta-analysis of a fixed effect model showed a statistically significant reduction in cystic kidney volume (CKV) between the two groups [RR = 1.127 (0.996, 1.276), P = 0.058]. Egger's test and funnel plot analysis indicated no publication bias for GFR, TKV, or CKV. Sensitivity analysis demonstrated that the study results were robust. Conclusions: Octreotide long-acting release has a certain effect on reducing cystic kidney volume in patients with ADPKD but shows no significant effect on GFR or TKV and does not increase the risk of adverse reactions. These findings provide a certain reference for the clinical treatment of ADPKD; however, additional high-quality studies are still needed for further validation. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251242104.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.